Article Text

PDF
Infographic: we need minimum reporting standards for biologics
  1. Iain R Murray1,2,
  2. Andrew D Murray3,4,
  3. Andrew G Geeslin5,
  4. Ewan B Goudie2,
  5. Timothy O White2,
  6. Frank A Petrigliano6,
  7. Robert F LaPrade5
  1. 1Scottish Centre for Regenerative Medicine, The University of Edinburgh, UK
  2. 2Department of Trauma and Orthopaedics, The University of Edinburgh, UK
  3. 3Centre for Sport and Exercise Medicine, The University of Edinburgh, UK
  4. 4European Tour Golf, Wentworth Drive, Surrey, UK
  5. 5Steadman Philippon Research Institute, Vail, Colorado, USA
  6. 6Department of Orthopaedics, David Geffen School of Medicine, University of California, Los Angeles, USA
  1. Correspondence to Mr. Iain R Murray, Department of Trauma and Orthopaedics, University of Edinburgh, Royal Infirmary of Edinburgh, Little France Crescent, Edinburgh EH10 4SA, UK; Iain.Murray{at}ed.ac.uk

Statistics from Altmetric.com

Biologic therapies, including platelet rich plasma (PRP) and mesenchymal stem cells, are now widely used to treat a spectrum of sports injuries without robust clinical evidence of efficacy.1 2 Physicians have a duty to use biologic therapies responsibly, using the best available research evidence to guide treatment decisions for patients. A large number of variables, including processing details, …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.